nprnews_____ = ||| lubuntu at wor2|||New Coronavirus Vaccine Candidate Shows Promise In Early, Limited Trial||| kickerpage = |||no kicker pagenpr for NPRNEWS||| summarynpr = |||Cambridge, Mass.-based Moderna, Inc. is reporting preliminary data suggesting its COVID-19 vaccine is safe and appears to be triggering an immune response in test subjects.


New Coronavirus Vaccine Candidate Shows Promise In Early, Limited Trial

A view of Moderna headquarters in Cambridge, Mass., earlier this month. Moderna is touting preliminary data from a limited coronavirus vaccine trial.

Maddie Meyer/Getty Images


hide caption

toggle caption

Maddie Meyer/Getty Images


Coronavirus Live Updates


New Coronavirus Vaccine Candidate Shows Promise In Early, Limited Trial



Cambridge, Mass.-based Moderna, Inc. is reporting preliminary data suggesting its COVID-19 vaccine is safe and appears to be triggering an immune response in test subjects.


Loading…

FN: [[IN THE CLEAR]] Barr does not expect criminal investigation of Obama or Biden as result of Durham probe ((lubuntu at wor2))

=”https://www.foxnews.com/politics/barr-durham-probe“>Barr does not expect criminal investigation of Obama or Biden as result of Durham probe

FN: [[USAMA’S SOLDIER]] FBI cracks Pensacola Navy shooter's iPhone after Apple refuses to help, finds Al Qaeda contacts ((lubuntu at wor2))

=”https://www.foxnews.com/us/nas-pensacola-shooting-update“>FBI cracks Pensacola Navy shooter’s iPhone after Apple refuses to help, finds Al Qaeda contacts

AN: Abbott Labs pushes back on criticism that company’s rapid COVID-19 testing is highly inaccurate ((americasnewsroom__)) ((lubuntu at wor2))

John Hackett, vice president of applied research and technology at Abbott Labs, stands behind the tests on ‘America’s Newsroom.’

Create your own website, free on WordPress.com.Create your own website.
Start free